Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to three new employees. The company issued stock options totaling 26,350 shares with an exercise price of $9.98, matching the closing price on Nasdaq Global Market on June 2, 2025. These options, granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan, will vest 25% on June 2, 2026, followed by three equal annual installments until full vesting on June 2, 2029. The options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Loading...
Loading translation...
Positive
Company demonstrates ability to attract new talent with equity compensation
Stock options align employee interests with shareholder value
Negative
None.
News Market Reaction – RNAC
-0.80%
-0.80%Session move
In the trading session that priced this news, RNAC declined 0.80%, reflecting a mild negative market reaction.
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
What stock options did Cartesian Therapeutics (RNAC) grant to new employees in June 2025?
Cartesian Therapeutics granted options to purchase 26,350 shares at $9.98 per share to three new employees, with 25% vesting on June 2, 2026, and the remainder vesting in three annual installments until June 2, 2029.
What is the vesting schedule for RNAC's June 2025 employee stock options?
The options vest 25% on June 2, 2026, followed by three equal annual installments, becoming fully vested on June 2, 2029.
What is the exercise price of Cartesian Therapeutics' June 2025 inducement grants?
The exercise price is $9.98, which was the closing price of RNAC stock on the Nasdaq Global Market on June 2, 2025.
How long is the term of RNAC's June 2025 employee stock options?
